Page 32 - Compass Pathways News Today

Five years after participating in the first trial that used psilocybin as a therapy for treatment-resistant depression, Kirk Rutter tells Newsweek: "It really penetrated me emotionally."

The U.S. Food and Drug Administration put a clinical hold on Mind Medicine Inc’s application to start testing the psychedelic drug commonly known as LSD in…

Even though the use, possession or distribution of psychedelics is a felony, more Kansas Citians are embracing magic mushrooms as scientific evidence mounts that they can help deal with a variety of emotional disorders.

Investegate announcements from COMPASS Pathways, COMPASS Selected for Addition to NASDAQ Biotechnology Index

Investegate announcements from COMPASS Pathways, COMPASS Pathways announces changes in Executive Team

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Can psilocybin help relieve the mental health burden of clinicians affected by the COVID-19 pandemic? That’s a question University of Washington researchers aim…

Investegate announcements from COMPASS Pathways, Michael Falvey joins COMPASS Pathways as Chief Financial Officer

Investegate announcements from COMPASS Pathways, COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

Psilocybin can treat depression, alcoholism, PTSD, and even cluster headaches. Why is it still illegal?